A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Principal Investigator
Study Number
F18074
Summary
This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.
Phase
N/A
Contact
Available at the following location(s)
- Manchester
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms